Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
aducanumab
3
×
alzheimer's disease
biogen
3
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
3
×
gilead sciences
indiana blog main
indiana top stories
3
×
life sciences
national
3
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
3
×
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
affordable care act
biotech
bristol-myers squibb
cancer
clinical trials
deals
johnson & johnson
nonalcoholic steatohepatitis
novartis
seattle genetics
What
bio
roundup
biogen
biogen’s
drug
nash
new
news
activity
aducanumab
alzheimer’s
amyloid
angst
approval
approvals
bagged
billions
biopharmaceutical
brammer
clamped
companies
convo
covid
delays
developing
earlier
economic
effects
failure
failures
fast
fda
felt
including
ipo
isn’t
littered
lost
lot
medicines
Language
unset
Current search:
aducanumab
×
national
×
biogen
×
" detroit top stories "
×
" indiana top stories "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More